Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.
Hoppe JE, Kasi AS, Pittman JE, Jensen R, Thia LP, Robinson P, Tirakitsoontorn P, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Salinas DB, Zhu J, Chen YC, Rodriguez-Romero V, Sosnay PR, Davies G.
Hoppe JE, et al. Among authors: chen yc.
Lancet Respir Med. 2024 Dec 20:S2213-2600(24)00407-7. doi: 10.1016/S2213-2600(24)00407-7. Online ahead of print.
Lancet Respir Med. 2024.
PMID: 39756425
Free article.